Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
715 ICT01 plus low dose SC IL-2 produces a robust anti-tumor immune activation in advanced cancer patients (EVICTION-2 Study)
Compose a Response to This Article
Other responses
No responses have been published for this article.
